Lifesci Capital Reiterates Outperform Rating for Perspective Therapeutics (NYSEAMERICAN:CATX)

Perspective Therapeutics (NYSEAMERICAN:CATX)‘s stock had its “outperform” rating restated by stock analysts at Lifesci Capital in a research report issued on Monday, Zacks.com reports. Lifesci Capital also issued estimates for Perspective Therapeutics’ FY2024 earnings at ($0.12) EPS and FY2025 earnings at ($0.14) EPS.

A number of other equities analysts have also commented on the stock. Oppenheimer reiterated an “outperform” rating and set a $1.50 price target (up previously from $1.20) on shares of Perspective Therapeutics in a report on Monday, April 1st. B. Riley increased their price target on Perspective Therapeutics from $1.20 to $1.70 and gave the company a “buy” rating in a research note on Tuesday, April 9th.

Perspective Therapeutics Trading Down 4.3 %

Shares of NYSEAMERICAN CATX opened at 1.76 on Monday. Perspective Therapeutics has a 1 year low of 0.21 and a 1 year high of 1.90. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.07 and a quick ratio of 1.07. The company has a market capitalization of $1.03 billion, a P/E ratio of -17.60 and a beta of 1.43.

Insider Buying and Selling at Perspective Therapeutics

In other Perspective Therapeutics news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the stock in a transaction on Wednesday, March 6th. The stock was acquired at an average cost of 0.95 per share, for a total transaction of 57,409,487.05. Following the completion of the acquisition, the insider now owns 116,773,394 shares in the company, valued at approximately 110,934,724.30. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.52% of the company’s stock.

Institutional Investors Weigh In On Perspective Therapeutics

Large investors have recently bought and sold shares of the stock. ZWJ Investment Counsel Inc. bought a new position in shares of Perspective Therapeutics in the first quarter valued at $26,000. Bleakley Financial Group LLC acquired a new stake in shares of Perspective Therapeutics in the 1st quarter worth about $40,000. Simplicity Wealth LLC bought a new position in Perspective Therapeutics in the 1st quarter valued at about $40,000. Taylor & Morgan Wealth Management LLC boosted its stake in Perspective Therapeutics by 8.7% during the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock valued at $251,000 after purchasing an additional 50,000 shares during the last quarter. Finally, RIA Advisory Group LLC raised its stake in shares of Perspective Therapeutics by 1,313.4% in the first quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock worth $127,000 after purchasing an additional 99,293 shares during the last quarter. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.